Therapeutic effects of BM 12,531 (Prop. INN azimexon).
The antitumor effect of BM 12,531, 2-[2-cyanaziridinyl-(1)]-2[carbamoylaziridinyl-(1)]-propane (Prop. INN azimexon), on L1210 leukemia in mice is described. The immunostimulating compound BM 12,531 can also reduce the acute toxicity of X-irradiation in mice. The most effective doses in these experiments are 1 or 5 mg/kg twice a week, whereas 50 and 500 mg/kg twice a week decrease the therapeutic effect. The mortality of Candida-infected and irradiated mice is also reduced by oral administration of BM 12,531. BM 12,531 has synergistic effects with subtherapeutic doses of chloramphenicol in an experimental E. coli infection in mice.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001388:Aziridines / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy; D003520:Cyclophosphamide / Q000009:adverse effects; D005260:Female; D007939:Leukemia L1210 / Q000188:drug therapy; D051379:Mice
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D001388:Aziridines; D001389:Azirines; C016866:azimexon; D003520:Cyclophosphamide